Abcam, ab250079, Anti-AGXT antibody [EPR13232] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal AGXT antibody. Carrier free. Suitable for IP, WB and reacts with Human, Mouse samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR13232,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Human,
Applications:WB, IPSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab250079 is the carrier-free version of
ab178708
Mouse species is recommended by WB application. We have preliminary internal testing data to indicate this antibody may not react with mouse in IHC.
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Species reactivity
Rat: We have preliminary internal testing data to indicate this antibody may not react with this species.
Please
contact us
for more information.
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The biological target AGXT also known as alanine-glyoxylate aminotransferase plays an important role in human metabolism. It is a liver-specific enzyme with an approximate molecular weight of 43 kDa. AGXT is expressed primarily in liver peroxisomes where it catalyzes the transamination reaction that converts glyoxylate to glycine. This enzymatic activity is important for detoxifying glyoxylate which otherwise could accumulate and result in harmful effects. The expression level and activity of AGXT can be influenced by various metabolic conditions.
Biological function summary
The conversion of glyoxylate to glycine mediated by AGXT helps in maintaining cellular homeostasis. AGXT is not part of large protein complexes but it directly influences the pathways leading to amino acid metabolism. By converting glyoxylate into glycine this enzyme plays a part in managing the precursors necessary for the biosynthesis of other important biomolecules including serine and pyruvate. As glyoxylate is an important intermediary its conversion is essential for metabolic flux.
Pathways
AGXT has a significant role in the glyoxylate metabolic pathway and the glycine serine and threonine metabolism pathway. In these pathways it works closely with other enzymes like glycine decarboxylase and serine hydroxymethyltransferase. The proper functioning of these pathways ensures efficient energy utilization and detoxification in the human body. Any disruption can affect the balance of amino acid concentrations leading to metabolic disturbances.
AGXT is most prominently linked to primary hyperoxaluria type 1 (PH1) which is a rare genetic condition. In PH1 mutations in the AGXT gene lead to its dysfunctional enzyme causing the accumulation of oxalate and subsequent kidney stone formation and renal failure. The disease connection places AGXT in relation to key proteins involved in oxalate metabolism and renal function such as glycolate oxidase. Understanding AGXT's role in these disorders opens pathways for therapeutic interventions and advanced research into metabolic regulation.